2025_11_04/LS-youtube-1762257079795
2025_11_04/LS-instagram-1762257129651
2025_11_04/LS-linkedin-1762257171623
2025_11_04/LS-tiktok-1762257218283
2025_10_22/social-1761147020798
2025_10_22/telegram_(3)-1761147112036

Iscriviti al canale

2025_11_04/LS-whatsapp-1762257262401
2025_11_04/LS-telegram-1762257310710
14 dicembre 2025 - Aggiornato alle 06:10
×
2025_11_04/LS-youtube-1762257079795
2025_11_04/LS-instagram-1762257129651
2025_11_04/LS-linkedin-1762257171623
2025_11_04/LS-tiktok-1762257218283
2025_10_22/social-1761147020798
2025_10_22/telegram_(3)-1761147112036
last issue

Leggi

Abbonati

☰

UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting

Redazione La Sicilia

Redazione La Sicilia

10 Dicembre 2019, 09:09

La nostra app
SEGUICI
2025_11_04/LS-youtube-1762257079795
2025_11_04/LS-instagram-1762257129651
2025_11_04/LS-linkedin-1762257171623
2025_11_04/LS-tiktok-1762257218283
2025_10_22/social-1761147020798
2025_10_22/telegram_(3)-1761147112036

Copyright © 2025 • La Sicilia Investimenti S.p.A. • P.I. 03133580872 • All rights reserved• Powered by GMDE srl